EPO and cancer: Further trials are required to clarify whether high Epo predisposes to or results from metastatic progression and whether the suspected mobilization/recruitment of EpoR-positive cancer-initiating cells is the likely cause of pro-malignant effects for adverse outcome in rhEPO-treated oncologic patients.